Showing posts sorted by date for query chantix. Sort by relevance Show all posts
Showing posts sorted by date for query chantix. Sort by relevance Show all posts

Friday, November 16, 2012

Pfizer CEO Must Testify in Chantix Trial, Lawyer Says - Bloomberg

via bloomberg.com

Pfizer Inc.’s top executive must testify in court about claims the company’s anti-smoking drug Chantix causes depression and other psychiatric disorders, a lawyer for an Alabama man suing over the medication said.
Attorneys for Billy Bedsole have subpoenaed Ian Read, Pfizer’s chief executive officer, and two other officials to testify live at the trial of Bedsole’s claims that the anti- smoking drug caused his breakdown and forced him to be institutionalized, said Ernest Cory, one of Bedsole’s lawyers. U.S. District Judge Inge Johnson has denied Pfizer’s request to throw out the subpoenas, Cory added.
The trial, which would be the first patient lawsuit over Chantix to be heard by a jury, is slated for Jan. 22, 2013, in federal court in Florence, Alabama, according to court records.
“I think the jury will look forward to having Mr. Read testify in Alabama and he should look forward to defending Chantix,” Cory said in an interview today.
Last month, New York-based Pfizer, the world’s biggest drugmaker, reached a confidential settlement with the widow of a Minnesota man who killed himself after taking Chantix. The case on behalf of the family of Mark Alan Whitely had been slated to begin Oct. 22 in Florence.
Chris Loder, Pfizer’s spokesman, declined to immediately comment on the subpoenas for the executives.
‘Erratic Behavior’
Read, along with Pfizer executives Diana Hughes and Carl Wilbanks, had been subpoenaed in the Whitely case before it settled. The same three executives have been called to testify in Bedsole’s case, Cory said.
Bedsole, an employee with a local power company, took Chantix in 2007 in hopes of being able to quit smoking, Cory said. Instead, the drug caused him to develop suicidal thoughts, “memory loss, depression, erratic behavior, mood swings, anxiety and hospitalization,” according to court filings.
Bedsole’s case and other lawsuits have been combined in a multidistrict litigation before Johnson in Alabama for pretrial evidence-gathering and the first trials.
The suits claim Chantix causes depression and other psychiatric disorders, some so severe that patients attempt or commit suicide. The plaintiffs allege that Pfizer knew of a link between Chantix and suicide and failed to sufficiently warn patients.
Pfizer has denied that Chantix was the cause of Bedsole’s ailments or that the company withheld information about the drug. The company provided warnings on the drug’s package insert of reports of suicidal thoughts since 2006, its lawyers have said in court filings.
The consolidated cases are In re Chantix (Varenicline) Products Liability Litigation MDL 2092, 09-cv-2039 U.S. District Court, Northern District of Alabama (Florence). Bedsole’s case is Billy G. Bedsole Jr. v. Pfizer Inc. (PFE), 09-cv-2051 U.S. District Court, Northern District of Alabama (Florence).
To contact the reporters on this story: Jef Feeley in Wilmington, Delaware, at jfeeley@bloomberg.net; Margaret Cronin Fisk in Detroit at mcfisk@bloomberg.net
To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Posted via email from Jack's posterous

Wednesday, October 17, 2012

Chantix - let the games begin

Judge Denies Pfizer Request for Delay in Chantix Trial

A federal judge denied Pfizer Inc.'s (PFE) request to delay the start of the first product-liability trial surrounding its smoking-cessation drug Chantix, a delay the company said was needed because of newly released clinical data.

New York-based Pfizer is facing more than 2,600 lawsuits in federal court containing accusations that the smoking-cessation drug Chantix caused users to commit suicide or experience other mental-health problems, and that the drug maker failed to adequately warn of these risks. Safety concerns surrounding the drug have hurt its sales growth.

The first trial is scheduled to begin Monday in federal court in Alabama, and stems from a lawsuit brought by a Duluth, Minn., woman alleging her husband's use of Chantix caused him to commit suicide in 2007. Judy Whitely accused Pfizer of failing to properly warn of the risks before her husband Mark began using Chantix, and she is seeking damages.

Pfizer has denied the allegations, arguing in court papers that there is no evidence Chantix causes suicide-related events, and that it has properly warned of the various potential risks of the drug.

Tuesday, lawyers for Pfizer filed a motion seeking to delay the trial's start until Jan. 22, because the company released results Tuesday of a clinical trial involving Chantix. The study found Chantix was more effective than a placebo in helping people with past or present depression quit smoking, and there was no difference between the drug and a placebo in measures of psychiatric health, according to Pfizer's press release.

Pfizer asked a federal judge to delay the trial "to allow all parties to complete discovery and any pre-trial motion practice" related to the new clinical data, according to a motion filed by Pfizer Tuesday.

Amy Schulman, Pfizer's general counsel, said, "It's a time-honored legal principle that the law should follow science and not lead it," and Pfizer is asking the court to delay the start of the trial in order for the new data on the safety of Chantix to be weighed.

"The court should want a full and complete record before it, and in order to ensure that, the trial should be delayed to permit this evidence to be explored," she said.

However, U.S. District Judge Inge Prytz Johnson denied Pfizer's request later Tuesday. She wrote that Pfizer performed the study and controlled the release of its results, and noted more than 90 potential jurors have already been summoned for consideration to serve on the trial jury.

"Defendant's concern about litigation getting ahead of science does not create any cause for a sudden halt to litigation which has been pending since 2009, based on a study for which defendant controlled when the results were made public," the judge's ruling said.

Tara D. Sutton, an attorney for Ms. Whitely, declined comment.

In addition to preparing its defense, Pfizer is trying to keep its chief executive, Ian Read, out of the courtroom. A U.S. District Court judge has permitted Ms. Whitely's lawyer to call Mr. Read as a witness in the trial, but Pfizer last week appealed the decision, arguing his appearance would be burdensome and unnecessary. An appellate court decision is pending.

Chantix was initially a Pfizer success story when it was introduced in 2006, with the company predicting annual sales would eventually top more than $1 billion. Early sales were brisk because clinical trials showed it was an effective aid to help people stop smoking.

But safety concerns soon emerged, including a 2007 report that a rock musician in Texas engaged in erratic behavior after using Chantix, which preceded his shooting death.

The U.S. Food and Drug Administration and watchdog groups began issuing alerts about the drug's safety, including the FDA's 2009 requirement that the drug's prescribing label carry a prominent, "black box" warning of the risk of serious mental health events including suicidal thoughts and hostility associated with Chantix.

Sales growth has stalled out. For the first half of 2012, Chantix sales fell 10% to $350 million.

The lawsuits filed against Pfizer have generally alleged use of Chantix caused suicides, suicide attempts and other injuries.

The lawsuits also accuse Pfizer of improperly promoting the drug as a safe medication. They say Pfizer didn't include sufficient warning about neuropsychiatric risks in the Chantix prescribing label, even after Pfizer made revisions to the label in 2007 and 2008. The lawsuits allege that Pfizer should have issued the black-box warning for Chantix much sooner than 2009, and even the 2009 warning is insufficient.

In September, Ms. Whitely's lawyers served a subpoena to summon three Pfizer officials including Mr. Read to testify as witnesses at the trial. Mr. Read served as head of Pfizer's worldwide pharmaceutical operations when Chantix was launched, before ascending to the CEO post in 2010.

Pfizer asked the court to quash the subpoena, saying the court has no authority to enforce a subpoena issued to an officer of a party to a lawsuit who lives or works more than 100 miles from the courthouse.

Pfizer also noted Mr. Read has given a five-hour videotaped deposition that can be used at the trial. Pfizer said Mr. Read's responsibilities for marketing and commercial activities surrounding Chantix aren't relevant to the case because there is no evidence Mr. Whitely or his doctor ever saw any Chantix marketing materials.

Judge Johnson ruled on Oct. 4 that Mr. Read was subject to subpoena because he is a Pfizer officer, and that prior court rulings have allowed subpoenas on officers beyond the 100-mile radius.

Pfizer appealed the ruling to the U.S. Court of Appeals for the 11th Circuit in Atlanta.

http://www.foxbusiness.com/news/2012/10/16/judge-denies-pfizer-request-for-delay-in-chantix-trial/?

Saturday, September 22, 2012

Oh the irony!

US Govt Suicide Initiative Ignores Suicide-Linked Drugs


Wednesday, 19 September 2012, 4:39 pm
Article: Martha Rosenberg
US Government Suicide Initiative Ignores Suicide-Linked Drugs

by Martha Rosenberg
September 18, 2012



It would be laughable if it weren't tragic. Last week US Surgeon General Regina Benjamin introduced a plan to stem the nation's growing suicide rate without addressing the nation's growing use of suicide-linked drugs.

Antidepressants like Prozac and Paxil, antipsychotics like Seroquel and Zyprexa and anti-seizure drugs like Lyrica and Neurontin are all linked to suicide in published reports and in FDA warnings. (Almost 5,000 newspaper reports link antidepressants to suicide, homicide and bizarre behavior.) Asthma drugs like Singulair, antismoking drugs like Chantix, acne drugs like Accutane and the still-in-use malaria drug Lariam, are also linked to suicide.

The US's suicide rate has risen to 38,000 a year, says USA Today, after falling in the 1990s. The rise correlates with the debut of direct-to-consumer drug advertising in the late 1990s, the approval of many drugs with suicide links and more people taking psychoactive drugs for lifestyle problems.

Dr. Benjamin announced that federal grants totaling $55 million will save 20,000 lives in the next five years through suicide hotlines, more mental health workers in the VA, better depression screening and Facebook tracking of suicidal messages. Nowhere, including in the suicide-racked military, does she suggest looking at the overmedication which has gone hand-in-hand with the deaths. A month earlier, it was announced the Army has awarded $3 million to a scientist to develop a thyroid related nasal spray to combat suicidal thoughts, also ignoring overmedication.

Suicide increased more than 150 percent in the Army and more than 50 percent in the Marine Corps between 2001 to 2009, reported Military Times displaying graphs of the suicide and prescription drug increases, in a print edition, that are similar enough to be laid over one another. One in six service members was on a psychoactive drug in 2010 and "many troops are taking more than one kind, mixing several pills in daily 'cocktails' for example, an antidepressant with an antipsychotic to prevent nightmares, plus an anti-epileptic to reduce headaches--despite minimal clinical research testing such combinations," said Military Times.

Eighty-nine percent of troops with posttraumatic stress disorder (PTSD) are now given psychoactive drugs and between 2005 and 2009, half of all TRICARE (the military health plan) prescriptions for people between 18 and 34 were for antidepressants. During the same time period, epilepsy drugs like Topamax and Neurontin, increasingly given off-label for mental conditions, increased 56 percent, reports Military Times. In 2008, 578,000 epilepsy pills and 89,000 antipsychotics were prescribed to deploying troops. What?

Nor is the suicide rate going down as troops withdraw from Iraq and Afghanistan. In July, 2012, there were 38 Army suicides says USA Today and in July of 2011, there were 32. According to the Army's in-depth Health Promotion, Risk Reduction and Suicide Prevention Report in 2010, 36 percent of the troops who killed themselves had never even deployed.

Why are such drugs, which affect reaction time, motor skills, coordination, attention and memory even allowed during active duty? And why are they prescribed to soldiers who are at the exact age--young adults--that is most at risk for suicide according to warning labels?

Nor are troops the only cash cows for Big Pharma. One in four women are on psychoactive drugs according to published reports and millions of children are on psychoactive drugs, especially poor and those with disability status.

When the FDA first put suicide warnings on antidepressants for young people in the mid 2000s, Big Pharma linked psychiatrists like Charles Nemeroff argued that suicides would go up if doctors and patients were scared off by the black box warnings. Though the argument was absurd--is the nation fat because fen-phen was withdrawn?--the theory got play in the mainstream and medical press until it was proven wrong.

Yet as the Surgeon General and HHS proved this week, the government is still in denial about suicide and the elephant in the room called Big Pharma. Instead of spending millions on counselors, crisis lines, and "awareness campaigns" why doesn't it look at the millions it's spending on suicide-linked drugs?

*************
More information about overmedication of troops and suicide-linked drugs is found in Martha Rosenberg's recently published Born With a Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health available in book stores, libraries and online.

http://www.scoop.co.nz/stories/HL1209/S00111/us-govt-suicide-initiative-ignores-suicide-linked-drugs.htm?

Monday, March 26, 2012

Federal judge sets dates for first two trials against Pfizer over Chantix stop-smoking drug

via blog.al.com

BIRMINGHAM, Alabama -- A federal judge in north Alabama has set dates for the first two trials to be held in thousands of civil lawsuits filed nationwide against pharmaceutical manufacturer Pfizer Inc. over Chantix, a drug to help people stop smoking.
The two lawsuits also are part of a pool of eight selected by U.S. District Judge Inge Johnson to be bellwether -- or test -- cases in the litigation. Johnson is to preside over those first trials.
Johnson, in a recent order, set the first case for trial on Oct. 22 in a lawsuit originally filed by Duluth, Minn., resident Judy Ann Whitely against Pfizer for the wrongful death of her husband. Mark Alan Whitely began using Chantix on Nov. 20, 2007, and he committed suicide.
As with many of the lawsuits that were filed using a standard form for the Chantix litigation, the Whitely suit does not give any details of Mark Alan Whitely's suicide, whether he had any other problems, or the date of his death. Efforts to reach the attorneys in Minnesota for Whitely were unsuccessful last week.
The next case is set for Jan. 22, 2013. In that case, a representative of the estate of Sandra Corey, of Jacksonville, Ore., is suing Pfizer for wrongful death. That lawsuit claims that Corey began using Chantix on Oct. 2, 2007, and that the drug caused depression and suicide by gunshot on July 24, 2008.
If both the Whitely and Corey cases are tried as scheduled, the third case would be one filed in 2009 by a Demopolis man, Billy Bedsole Jr., who claims he suffered insomnia, severe anxiety, severe depression, erratic behavior, suicidal ideation and hospitalization after taking Chantix.
If the first two cases are settled, dismissed or resolved, then the Bedsole case would be the first case tried, according to Johnson's order.
While the first two cases slated to be tried in the Chantix litigation deal with completed suicides, the vast majority of the cases deal with claims that Chantix caused various other problems.
So far, 2,498 Chantix cases have been filed against Pfizer from across the country, according to the Birmingham-based Cory Watson Crowder & DeGaris law firm, which is the lead plaintiff firm in the cases. There are 68 additional cases pending in New York state courts, according to that law firm.
The multidistrict litigation process aims to consolidate civil lawsuits with similar claims under judges who will oversee trial preparation to eliminate duplication and inconsistent rulings, and save money for plaintiffs, defendants and the courts.

Posted via email from Jack's posterous

Thursday, November 03, 2011

New US study says Chantix raises suicide risks

CHICAGO (REUTERS) - Pfizer's smoking cessation drug, Chantix, carries too many risks and should only be tried when other treatments fail, US researchers said on Wednesday.

Chantix was eight times more likely to be linked with a reported case of suicidal behaviour or depression than other nicotine replacement products, such as the nicotine patch, they said.

The findings, which Pfizer said were flawed, contradicted two studies released last month by the US Food and Drug Administration that showed Chantix (sold as Champix outside the United States) did not increase the risk of being hospitalised for psychiatric problems such as depression.

The agency at the time acknowledged those studies were flawed because they were too small to identify rare events and captured only cases severe enough to land people in the hospital.

Posted via email from Jack's posterous

Tuesday, July 05, 2011

Chantix: Quit Smoking, But Risk Your Heart? - ABC News

Media_httpaabcnewscom_ljjki

On the heels of the FDA's admission that Chantix, Pfizer's smoking cessation drug, may aggravate heart problems in those with cardiovascular disease, new research suggests that they're not the only ones at risk. Chantix may increase the risk of heart attack and other adverse events for those with a clean bill of cardiovascular health.

Though concerns over Chantix' effect on the heart were raised during the drug's approval process in 2006, the FDA's recent move to include a cardiovascular warning in the drug's safety information marks the first time the organization has publicly discussed such potential risks. It's a move that is a long time coming for Dr. John Spangler, co-author on the new research, a meta-analysis published Monday in the Canadian Medical Association Journal.

Posted via email from Jack's posterous

Thursday, June 16, 2011

Pfizer's Chantix may raise heart risk: FDA - MarketWatch

Pfizer Inc.'s smoking cessation aid Chantix may increase the risk of heart attack in patients with cardiovascular disease, the Food and Drug Administration said Thursday in a safety announcement. In a 700-patient study, half were given Chantix and half were given a placebo, the FDA said. While 47% of the Chantix group went without smoking for four weeks compared with 14% in the placebo group, 2% of the Chantix group had a non-fatal heart attack compared with 0.9% in the placebo group. "Cardiovascular adverse events were infrequent overall, however, certain events, including heart attack, were reported more frequently in patients treated with Chantix than in patients treated with placebo," the FDA said.

Posted via email from Jack's posterous

Friday, May 27, 2011

Scores of Chantix suicides overlooked - msnbc.com

“We’ve had a major breakdown in safety surveillance,” said Thomas J. Moore, the ISMP senior scientist who analyzed the data. The serious problems — including reports of completed suicides, suicide attempts, aggression and hostility and depression — had been mixed among some 26,000 records of non-serious side effects such as nausea and rashes, with some dating back to 2006, the year Chantix, or varenicline, was approved.

They echo previous claims that the drug can induce extreme reactions in people trying to quit cigarettes, including vivid nightmares, crippling depression and sudden, violent outbursts.

“It’s really chilling,” said Moore, who analyzed 26 Chantix reactions in a paper published in the September 2010 issue of the Journal of Pharmacotherapy. "This seems to unleash something in people. It can be violence to anything around."

Moore's case studies describe "inexplicable and unprovoked" reactions in Chantix patients with no previous history of violence or mental illness, including:

  • A 24-year-old woman who started beating her boyfriend in bed because "he looked so peaceful" and later attempted suicide;
  • A 42-year-old man who punched a stranger at a bowling alley;
  • A 47-year-old woman who died after she came out of a room, yelled at her daughters and then shot herself.

Posted via email from Jack's posterous

Wednesday, January 05, 2011

Alabama court to hear lawsuit against Pfizer's Chantix


BIRMINGHAM, Alabama (Reuters) - A federal court in Alabama will centralize at least 1,200 civil lawsuits against Pfizer Inc over its smoking-cessation drug Chantix, which plaintiffs say can lead to suicide.
U.S. Judge Inge Johnson (not pic) of the Northern District of Alabama is handling pretrial proceedings and will preside over the civil trials unless the parties settle out of court, the court said.
"The centralization will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation," according to court documents.
Worldwide sales of Chantix for the third quarter of 2010 stood at $163 mln, up 5 pct from one year earlier.
About 60 percent of the cases allege suicide, attempted suicide or other overt acts of injury, Ernest Cory, lead counsel for the plaintiffs, said on Tuesday.
"Chantix was put on the market without adequate warnings and it is a dangerous drug ... Many people prior to July 2009 were not aware that this drug was not tested in any patient with any mental condition," he said.
"As a result, it appears that several thousands of people have been seriously injured or have died from using this drug, and that's a tragedy for them and their families. That's a tragedy that didn't need to happen," he said.

Monday, January 03, 2011

Pfizer’s Chantix Runs Short in Japan After Cigarette Tax Rise

The tax increase should also have been a bonanza for Pfizer, the world’s biggest pharmaceutical company, which makes the leading drug to help smokers break the habit.

Instead, it became a missed opportunity.

Despite ample notice of the change, Pfizer failed to produce enough of the drug, Chantix, which is sold as Champix in Japan. When tens of thousands of would-be quitters rushed to their doctors for prescriptions, Pfizer was overwhelmed.

Posted via email from Jack's posterous

Tuesday, December 28, 2010

Martha Rosenberg | The Year in Pills

Martha Rosenberg | The Year in Pills

Published on Dec 27, 2010 - 7:35:40 AM

By: Martha Rosenberg

martharosenberg_1.jpgDecember 27, 2010 - 2010 will go down as the year the diet pill Meridia and pain pill Darvon were withdrawn from the market and the heart-attack associated diabetes drug Avandia was severely restricted.

But it was also the year the Justice Department filed the first criminal, not civil, charges against a drug company executive, former GSK VP and assistant general counsel Lauren Stevens.

And the year prominent psychiatrists Charles Nemeroff and Alan Schatzberg were accused of writing an entire book to teach primary care physicians p$ychopharmacology.

Still most of the action was promotion of dangerous pills, many of which should never have been approved.

Here is 2010's Hall of Shame.

Yaz and Yasmin

Soon after Bayer launched the pill Yaz in 2006, billing it as going "beyond birth control," 18-year-olds were coming down with blood clots, gall bladder disease, heart attacks and even strokes. FDA ordered Bayer to run correction ads that detail the drugs' risks though Yaz sales are still brisk. In fact, financial analysts attribute a third quarter slump to a Yaz generic coming online, not dangerous side effects.

Lyrica, Topamax and Lamictal

In August FDA ordered a warning on the seizure drug Lamictal for aseptic meningitis (brain inflammation) but it is still the darling of military and civilian doctors for unapproved pain and migraine uses. All three drugs increase the risk of suicidal thoughts and behaviors according to their mandated labels, in addition to the memory and hair loss patients report.

Humira, Prolia and TNF Blockers

The drug industry's highly promoted biologic drugs are made from genetically engineered hamster cells and suppress the immune system, inviting tuberculosis and several cancers. Yet Humira is advertised to healthy people for "clearer skin" and Prolia is advertised to prevent osteoporosis in healthy women.

Chantix

After 397 FDA cases of possible psychosis, 227 domestic reports of suicidal behaviors and 28 actual suicides, the government banned pilots, air-traffic controllers and interstate truck and bus drivers from taking the antismoking drug Chantix in 2008. Its neuropsychiatric effects were immortalized when New Bohemians musician Carter Albrecht was shot to death in 2007 in Texas by a neighbor after acting aggressively on the Chantix.

Ambien

The sleeping pill Ambien was immortalized as the drug Tiger Woods reportedly cavorted with his consorts on and former US Rep. Patrick Kennedy crashed his Ford Mustang on, while driving to Capitol Hill in the middle of the night to "vote" in 2006. Law enforcement officials say it has increased traffic accidents from people who drive in a black out and don't even recognize arresting officers.

Tamoxifen

Is it a coincidence that Tamoxifen maker AstraZeneca founded Breast Cancer Awareness Month and makes carcinogenic agrochemicals that cause breast cancer? As a breast cancer prevention drug, an American Journal of Medicine study found the average life expectancy increase from Tamoxifen was nine day . Public Citizen says for every case of breast cancer prevented on Tamoxifen there is a life-threatening case of blood clots, stroke or endometrial cancer.

Lipitor and Crestor

Why is Lipitor the best selling drug in the world? Because every adult with high LDL or fear of high LDL is on it. And also 2.8 million children, says Consumer Reports. All statins can cause muscle breakdown called rhabdomyolysis. And Crestor is so linked to the side effect, Public Citizen calls it a Do Not Use and the FDA's David Graham named it one of the five most dangerous drugs before at a Congressional hearing.

Boniva

Boniva and other bisphosphonate bone drugs are a good example of FDA approving once unapprovable drugs by transferring risk onto the public's shoulders. The list of dangers on the label includes waiting 60 minutes before eating or drinking anything except plain water, never taking the drug with mineral water, sparkling water, coffee, tea, milk, juice or other oral medicine, including calcium, antacids, or vitamins and not lying down after you take it.

Prempro

Pfizer's hormone drug Prempro is linked to a 26 percent increase in breast cancer, 41 percent increase in strokes, 29 percent increase in heart attacks, 22 percent increase in cardiovascular disease and double the rate of blood clots. But its cognitive and cardiovascular "benefits" are being tested right now at major universities to debut an HT "Light," hoping the public has a short memory.

Prozac, Paxil, Zoloft, SSRIs

Selective serotonin reuptake inhibitor (SSRIs) antidepressants like Prozac, Paxil, Zoloft and Lexapro probably did more to inflate drug industry profits than Viagra. But many say the drugs have also inflated police blotters. In addition to 4,200 published reports of SSRI-related violence, including the Columbine, Red Lake and NIU shootings, SSRIs can cause serotonin syndrome and gastrointestinal bleeding when taken with certain drugs. Paxil is linked to birth defects.

Effexor, Cymbalta, Pristiq, SNRIs

Selective norepinephrine reuptake inhibitors (SNRIs) are like their SSRIs chemical cousins except their norepinephrine effects can modulate pain, which has ushered in your-depression-is-really-pain, your-pain-is-really-depression and other crossover marketing. SNRI's are also harder to quit than SSRIs. 739,000 web sites address "Effexor" and "withdrawal."

Seroquel, Zyprexa, Geodon, atypical antipsychotics

The antipsychotic Seroquel tops 71 drugs on the FDA's January 2010 adverse event report and is linked to unexplained troop deaths and many research scandals. But it's the fifth biggest-selling drug in the world. Atypical antipsychotics cause weight gain and diabetes, the tardive dyskinesia they are marketed to prevent and death in the demented elderly. Yet FDA approved Zyprexa and Seroquel for children last year and the new atypical antipsychotic, Latuda this year. Maybe the FDA is bipolar.

Ritalin, Concerta, Strattera, Adderall and ADHD drugs

ADHD drugs rob "kids of their right to be kids, their right to grow, their right to experience their full range of emotions, and their right to experience the world in its full hue of colors," says Anatomy of an Epidemic author Robert Whitaker. But they are a gold mine for the drug industry. During an August conference call with financial analysts, Shire specialty pharmaceuticals president Mike Cola lauded the "very dynamic ADHD market," and the "co-administration market" (in which kids don't need one drug but several.

Gardasil and Cervarix vaccines

A pharma-government plot to inoculate the public with dangerous vaccines? Maybe not but why are governors like Texas' Rick Perry mandating vaccination of girls for HPV? And why was University of Queensland lecturer Andrew Gunn silenced when he questioned the Gardasil vaccine? The HPV vaccine doesn't work for all viral strains, requires a boo$ter and is linked to 56 US girls' deaths as of September, according to the CDC.

Foradil Aerolizer, Serevent Diskus, Advair and Symbicort

Unlike drugs that look safe in trials and develop "safety signals" postmarketing, the long-acting beta agonists (LABA), salmeterol and formoterol, found in many asthma drugs, never looked safe. Studies link them to an increase in asthma deaths, especially in African-Americans and children. They may have contributed to 5,000 deaths said Dr. David Graham at FDA hearings about the controversial asthma drugs.

Singulair and Accolate, leukotriene receptor antagonists

Leukotriene receptor antagonists also never looked safe. Original FDA reviewers said asthma control "deteriorates" on Singulair and it may not be safe in children. Last month, Fox TV reported Singulair, Merck's top selling drug, is suspected of producing aggression, hostility, irritability, anxiety, hallucinations and night-terrors in kids, symptoms that are being diagnosed as ADHD. It is huckstered to parents by the trusted educational service Scholastic, Inc. and the American Academy of Pediatrics.

Martha Rosenberg's work has appeared in the Chicago Tribune, L.A. Times, San Francisco Chronicle, Boston Globe, Providence Journal. Arizona Republic, New Orleans Times-Picayune and other newspapers. Now she also shares her views with YubaNet.com's readers.

AddThis Social Bookmark Button

AddThis Feed Button

In the interest of fostering civil and issue-oriented discourse, YubaNet does not publish reader comments identified by anonymous Internet "handles" (fake user ID names like "farfromthinkin"). Your full and real name will be published with your comment. Your email address will not be shown, unless you specifically "uncheck" the box 'Hide my email.' By submitting a comment you consent to our rules.

Comments

No comments yet
Scriptsmill Comments Script-->

Posted via email from Jack's posterous

Thursday, December 16, 2010

Pfizer: Chantix - Quitting Smoking Can Be Dangerous to Your Health | Mother Jones

The exclusion of mentally ill subjects from drug trials, researchers say, can be justified in some cases; sometimes the people are too sick to give their consent—or they stray from the recommended course of treatment. (See our recent piece about corruption in clinical trials for the psych drug Seroquel.) Excluding them also makes it easier to evaluate trial results. But many experts say it also leaves the real-world effects of the drugs in question, since an estimated one in four Americans adults—close to 60 million people—suffer from a diagnosable mental disorder in a given year. (About 6 percent of US adults have a serious mental illness, adds the National Institute of Mental Health.)

These numbers are especially relevant for Chantix, given the higher rates of smoking among people with mental illness. In April 2010, for example, the Centers for Disease Control and Prevention reported that 43 percent of adults with depression smoke, compared with 22 percent of those who aren't depressed.

In November 2007, the FDA issued a notice that some patients taking Chantix had reported suicidal thoughts and erratic behavior. ("Posting this information," it clarified, "does not mean that the FDA has concluded there is a causal relationship between the drug products and the emerging safety issue.") Two months later, the agency ordered revised labeling, indicating that Chantix's safety for mentally ill patients had not been established. The Federal Aviation Administration, meanwhile, banned pilots and air traffic controllers from using Chantix.

But it wasn't until July 2009 that the FDA belatedly embraced the notion of testing Chantix on the mentally ill. "There is a disproportionate [number who] smoke, and they would be potentially exposed to this drug," said Dr. Curtis Rosebraugh, an FDA drug evaluation official, in a media briefing. "We have no idea if that subgroup population is at higher risk or not, and so we do want to get some sense of that."

Posted via email from Jack's posterous

Thursday, July 15, 2010

OpEdNews - Article: Is Pfizer the BP of Drug Companies?

Martha Rosenberg - Writer

Pfizer is best known for Lipitor, a drug that brings cholesterol down and Viagra, a drug that brings other things up.
But the "world's largest research-based pharmaceutical company" which sits between Goldman Sachs and Marathon Oil on the Fortune 500, is also distinguished by an unrivaled series of corruption allegations.
In fact, to say Pfizer's been accused of wrongdoing is like saying BP had an oil spill. Other drug companies have a portfolio of products, Pfizer has a portfolio of scandals including, but not limited to, Chantix, Lipitor, Viagra, Geodon, Trovan, Bextra, Celebrex, Lyrica, Zoloft, Halcion and drugs for osteoarthritis, Parkinson's disease, kidney transplants and leukemia.
During one week in June Pfizer 1) agreed to pull its 10-year-old leukemia drug Mylotarg from the market because it caused more not less patient deaths 2) Suspended pediatric trials of Geodon two months after the FDA said children were being overdosed 3) Suspended trials of tanezumab, an osteoarthritis pain drug, because patients got worse not better, some needing joint replacements (pattern, anyone?) 4) Was investigated by the House for off-label marketing of kidney transplant drug Rapamune and targeting African-Americans 5) Saw a researcher who helped established its Bextra, Celebrex and Lyrica as effective pain meds, Scott S Reuben, MD, trotted off to prison for research fraud 6) was sued by Blue Cross Blue Shield to recoup money it overpaid for Bextra and other drugs 7) received a letter from Sen. Charles Grassley (R-Iowa) requesting its whistleblower policy and 8) had its appeal to end lawsuits by Nigerian families who accuse it of illegal trials of the antibiotic Trovan in which 11 children died, rejected by the Supreme Court. And how was your week?
Nor does Pfizer back down when faced with legal troubles.
Even as it was under the probation of a 5-year Corporate Integrity Agreement (CIA) with Health and Human Services for withholding $20 million in Lipitor rebates owed to Medicaid in 2002, it off-label marketed its seizure drug Neurontin and entered into another CIA in 2004.
Worse, it bought Warner-Lambert in 2000, which made Neurontin, knowing the drug's marketing practices were under criminal investigation. (And knowing its Rezulin had been withdrawn.)
And even as it entered into its 2004 CIA for Neurontin, it was off-label marketing the seizure drug Lyrica, called Son of Neurontin, and three other meds, and had to enter into a third CIA, last year's $2.3 billion Bextra settlement which was the largest health care fraud settlement in US history.
The same day the settlement news broke, Pfizer announced it bought the drug giant Wyeth despite its thicket of Fen-Phen heart valve suits and Prempro cancer suits.
And there was more "bring 'em on" chutzpah.
After Vioxx and Pfizer's Bextra were withdrawn from the market for cardiovascular risks, Pfizer sought FDA approval for its Celebrex, the last legal COX-2 inhibitor, also suspected of cardiovascular risks, for use in children as young as two.
And in June, days before Pfizer suspended development of the osteoarthritis drug tanezumab for worsening joints, it touted the drug as "well-tolerated."
As a company, Pfizer, based in New York City with research headquarters in Groton, CT, looks better from the outside than the inside. Its Pac-Man like acquisition of drug companies, Warner-Lambert, Pharmacia (Searle, Upjohn), SUGEN, Vicuron, Rinat and Wyeth (also creating the world's biggest animal drug company) has created a silo structure in which the company's 90,000 employees in 90 countries feel unconnected to a corporate heartbeat. Loyalty is rare as employees in absorbed companies bought for their products alone fear getting pfired and 14,000 scientists bemoan that the company's biggies like Lipitor, Celebrex, Neurontin, Zithromax, Zyrtec and now Wyeth's Prempro weren't created inhouse.
Despite flying doctors to Caribbean resorts to attend drug pitches (by other paid doctors) and bestowing four figure honorariums on them and Enron moments like a Bextra sales extravaganza with acrobats, dancers and gigantic "fist" logo, Pfizer's Midtown Manhattan offices consist of unimpressive cubes.
After becoming the world's biggest drug company in 2000, Henry A. McKinnell, former Pfizer CEO and a Bushmate (replaced by less conservative Jeffrey B. Kindler) vowed to make Pfizer the "the world's most valued company to patients, to customers, to business partners, to colleagues, and to communities where we work and live." But thanks to the parade of damaging safety and ethics scandals, Esprit de corps is lacking except in some sales units.
 "Pfizer is a black hole," Peter Rost, MD, author of The Whistleblower: Confessions of a Healthcare Hitman and probably Pfizer's most famous former employee told AlterNet. "It is nothing but a maze of cobbled together drug companies that aggressively markets drugs it didn't create in a military-like command structure."
Still, Pfizer's vast product line, its $50 billion a year revenues -- exceeding some states' entire budgets -- and reputation for having the best trained sales reps make it the team to beat for competing salesmen and examples of Pfizer envy dot Cafepharma, the drug industry chatroom considered pharma's washroom wall.
"Glad they did it," wrote a poster about last year's Department of Justice (DOJ) Bextra settlement. "Pfizer is only sticking it to the American person when they perpitrate a fruad (sic) of this magnitude. The rest of you who sat by and said nothing are no better than a bunch of crooks. My father always said, 'you lie, you cheat, you steal; you can't do one without doing them all'. You must be so proud...I would take that name badge off when I walk into an office if I were you."
"If you think that Pfizer is the only drug company that has dealt with off-label promotion issues you are sadley (sic) mistaken," perpitrated the next poster.
"You are so right. All the other companies are doing it, so we did too. Waaah, waaah, waaaaah! (stomping my foot). It's not fair! It made us so much money! Patients don't matter, money does," wrote the next poster. Characterizations about wives and mothers followed.
Patients also resent Pfizer and have sued over Chantix, Lipitor, Celebrex, Bextra, Neurontin, Lyrica, Viagra, Zoloft and other drugs. Pfizer downplayed Lipitor's "serious and irreversible side effects" says Mark Jay Krum, an attorney representing plaintiffs in a class-action suit, and "is willing to promote the drug at any cost." Say that.
Even the DOJ calls Pfizer incorrigible. "...illegal conduct was pervasive throughout the company and stemmed from messages created at high levels within the national marketing team," it wrote in the Bextra sentencing memo. "Employees, including district managers, explained that they did not question their supervisors about the illegal conduct that they were being instructed to carry out, because to do so would be considered a 'CLM' or 'Career Limiting Move.'"
Still the FDA needs to take some blame for waving iffy Pfizer drugs through, especially under the 1992 Prescription Drug User Fee Act (PDUFA) in which drug companies "buy" accelerated approvals.
Why did the FDA allow Pfizer to make money for ten years on the leukemia drug Mylotarg, which was given an accelerated approval, and allow people to take it as guinea pigs for ten yearswhile "confirmatory" studies establishing its safety and efficacy were still outstanding? Patients who took Mylotarg while on chemotherapy had more deaths than those just on chemotherapy in a clear example of the lethal metrics of rushed through drugs.
Why was Pfizer's pain drug tanezumab, an injected monoclonal antibody made from bio-engineered immune cells, even considered for knee pain except for the profits in such Frakendrugs?
Why was Pfizer allowed to continue clinical trials on children, or anyone, after the FDA found Geodon overdoses in April -- and why is Geodon, rejected once by the FDA and promoted by Richard Borison MD who is in Hancock State Prison for research fraud -- hello -- on the market? Obama appointees Commissioner Margaret Hamburg, MD and principal deputy commissioner Joshua Sharfstein, MD come from public health backgrounds but it will be hard to turn the FDA ship around.
And speaking of dangerous drugs, what's up with Pfizer's anti-smoking drug Chantix?
In 2007, Texas musician Carter Albrecht, who played with Sorta and Edie Brickell & New Bohemians, became a poster boy for Chantix' unpredictable mental effects when he was fatally shot trying to kick in a neighbor's door. In 2008, with 988 adverse effects reported including seizures, heart trouble and suicides, the FDA banned airline pilots and air traffic controllers from taking it. Thanks for that. Last year it gave Chantix a black box warning to "highlight the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs."
Most pharma watchers agree that financial penalties, including last year's $2.3 billion Bextra settlement, won't upend Pfizer whose one year budget for R & D alone is in the billions. Yet the DOJ repeatedly lets Pfizer pawn off guilty pleas to the False Claims Act (which include a ban on Medicare, Medicaid and VA eligibility) on its shell companies and keep doing business with the government. Why?
"Pfizer is the largest drug company in the world and if you include its generics unit it makes literally hundreds of different drugs. Getting tough would mean no Lipitor, no Viagra, no Bacitracin, no Cipro, no Zithromax, no Sutent, et cetera," says Jim Edwards, a pharmaceutical reporter on Bnet and former managing editor of Adweek. "The government is not really in a position to be cutting itself off from all that medicine."
"So many Medicaid, Medicare and VA drugs come from Pfizer, the government would never convict them," agrees Peter Rost. "It would stop the drug flow."
And then there's lobby power.
Just as former Louisiana Republican representative Billy Tauzin left the House Committee on Energy and Commerce which oversees the drug industry and resurfaced as head of PhRMA, Pfizer recently hired Gregory Simon who served on Obama's transition team and as chief domestic policy advisor to Vice President Gore to head its "global policy effort." Its senior corporate counsel until 2008, Arnold Friede, had an FDA background and Pfizer's former senior vice president for worldwide public affairs, Richard Bagger, has re-emerged as New Jersey Governor Christopher Christie's chief of staff. Hey, you guys look familiar!
Nor does it hurt that CEO Jeffrey B. Kindler was elected a director of the Federal Reserve Bank of New York in 2009 and board chairman of the lobbying group PhRMA in 2010.
Even the Bextra settlement arouses cynicism since $102 million of it went to a doctor and five former Pfizer reps who served as whistleblowers on the case, one getting $51 million.
Isn't making big money off pharma how the trouble started?
An earlier version of this report appeared on Alternet.org

Friday, April 09, 2010

69 Wisconsin doctors show up on Pfizer payroll - JSOnline

Posted: April 8, 2010 |(7) Comments

Sixty-nine Wisconsin doctors were on the payroll of the world's largest drug company, Pfizer, during the last six months of 2009, working as speakers, consultants and researchers and pulling in more than $200,000 combined, according to a list made public by the company.

Topping the list of doctors who worked primarily as Pfizer speakers were Pamela Wilson, a retired Madison doctor who got $42,000 for the six-month period, and Daniel Duffy, a Cedarburg family practice doctor who got about $17,000.

Nationally, the average pay for a Pfizer speaker during that time period was $3,400.

During nine months last year, Duffy also pulled in about $50,000, mostly as a speaker, from Eli Lilly, which recently made public its doctor payments, according to the Lilly list.

Promotional speaking for drug companies can lead to biased information being delivered to other doctors who are expected to write more prescriptions for expensive brand-name drugs after hearing the talks, critics say.

The payments come as Pfizer joins Lilly and three other drug companies that in recent months have revealed payments to doctors, a practice that eventually will be mandated for all drug and medical device companies as part of the health care overhaul signed into law last month.

Together, the legislation and the drug company lists create a higher level of transparency for patients who, for the first time, can find out if the drugs they are on are being prescribed by doctors who are moonlighting for the companies that make the medicines.

But shining a light on the problem doesn't end it, doctors say.

"Some will always step up and take the money if the drug companies are offering it," said Norman Fost, director of the bioethics program at the University of Wisconsin School of Medicine and Public Health.

The law, which was co-sponsored by Sen. Herb Kohl (D-Wis.) and Sen. Chuck Grassley (R-Iowa), is designed to expose doctor conflicts of interest by requiring drug and medical device companies to report all gifts and payments to the U.S. Department of Health and Human Services.

The department will post the information on a Web site and can levy fines of up to $150,000 a year on companies that don't comply with the law.

Drug company payments to doctors have become a huge industry, Kohl said in an interview.

"Patients have every right to be aware of what their doctors are receiving," said Kohl, who has been trying to get the Physicians Payments Sunshine Act passed since 2006. Grassley and Kohl have been investigating financial relationships between doctors and the drug and medical device industry.

While the legislation won't take effect until 2013, the preliminary lists put out by Pfizer, which made its list public last week, and four other companies provide the first real insight into the pervasiveness of conflicts of interest by doctors moonlighting for drug companies.

The names of nearly 200 Wisconsin doctors and 15,000 nationally show up on the lists of just those five companies.

Doctors cautioned that merely creating lists of drug company payments to doctors does not put an end to the misleading, costly and potentially harmful information that can come when doctors are used to promote expensive drugs.

"Most of the major pharmaceutical companies have shown they are not trustworthy," Fost said.

In the last few years, several drug companies have been investigated by the federal government for illegal promotion of their medications, leading to fines and other payments totaling billions of dollars.

In addition, the lists may not be complete, said Eric Campbell, an associate professor at Harvard Medical School.

"I have absolutely zero confidence in these lists until they are audited by an independent third party," he said.

Pfizer's includes payments to 4,500 doctors and other health care professionals who got payments totaling $35 million, including about $20 million for speaking and consulting.

In Wisconsin, 69 professionals got payments ranging from less than $1,000 up to $42,000 each for marketing and drug development activities.

Pfizer's list of doctor payments was mandated as the result of a huge government investigation of illegal promotion of its drugs for unapproved purposes, including the use of doctor speakers.

Pfizer spokeswoman Kristen Neese said the list is designed so patients can look up their doctors.

It is the latest in a series of developments at the company designed to increase transparency, she said.

However, the list also was mandated by a corporate integrity agreement Pfizer signed in August.

It joins GlaxoSmithKline, Eli Lilly, Merck and Cephalon, which have put out similar lists in recent months. Like Pfizer, the Lilly and Cephalon lists were part of settlements of government investigations of illegal off-label promotion of drugs that included having doctors give speeches to other doctors.

The Pfizer drugs included Geodon, a medication approved to treat bipolar disorder that allegedly was illegally promoted for other conditions such as depression, anxiety, dementia, attention deficit disorder, autism and obsessive compulsive disorder, including in children.

The company offered illegal payments to doctors to induce them to promote and prescribe Geodon, according to the settlement agreement.

So-called off-label promotion of drugs for unapproved uses can be harmful to the health of patients.

Last year, Eli Lilly was found to have illegally marketed Zyprexa, a drug approved to treat only schizophrenia and bipolar disorder, for elderly patients with sleep disorders, agitation, hostility and dementia, according to the U.S. Department of Justice and details it released about the settlement. Lilly hired doctors to speak to other doctors about using Zyprexa off-label, though the company knew the drug caused weight gain, which could lead to high blood sugar and diabetes, according to the settlement.

The drug is a sedative that calms hallucinations.

Duffy, the Cedarburg family practice doctor, lectures locally and nationally on bipolar disorder and depression. For instance, in 2005 Pfizer sponsored a talk by him about bipolar disorder at a medical conference in Green Bay.

He did not respond to several attempts to reach him.

It is not known what Duffy discussed in his talks for Pfizer. The company declined Wednesday to answer questions about Duffy's speaking.

Lilly spokeswoman Carole Puls said he was paid to take part in two Zyprexa-related activities for the company in 2009, including a training program for Zyprexa speakers.

In October, the Wisconsin Academy of Family Physicians gave Duffy its 2009 Family Medicine Educator of the Year Award.

Wilson, a retired University of Wisconsin-Madison specialist in pulmonary medicine, said she gave three talks involving Pfizer's controversial drug Chantix during six months of 2009.

She declined to say how many Chantix talks she gave in the last two years.

"I have been an advocate for the prevention and treatment of lung disease and tobacco use throughout my professional career," she said in an e-mail.

Last year, Chantix and another smoking cessation drug, Zyban, got the strongest safety warning from the Food and Drug Administration. The drugs were associated with serious mental health risk.

Posted via web from Jack's posterous

Friday, January 15, 2010

Pfizer - Chantix: here come the lawsuits


Back stories here

NEW YORK (Reuters) - Three personal injury lawsuits were filed against Pfizer Inc on Thursday, claiming its smoking-cessation drug Chantix caused attempted suicides or death.

The suits, all filed in New York State Supreme Court in Manhattan by the same plaintiffs' law firm, claim Pfizer failed to notify doctors and patients about dangers the company allegedly knew about the pill -- including depression and suicidal thoughts--at the time the plaintiffs took the medicine.

And even though Pfizer subsequently added warnings to its package insert, the law firm alleged the drug label is still inadequate.

Pfizer introduced Chantix in the United States in 2006, with hopes it would become a huge product that would help revive flagging company profits, but its sales have wilted amid concern about side effects.

"Defendant intentionally, recklessly, and/or negligently concealed, suppressed, omitted, and/or misrepresented the risks, dangers, defects and disadvantages of Chantix," attorney Marc Grossman alleged in all three lawsuits.

Grossman is with the Mineola, New York law firm of Sanders Viener Grossman LLP.

Source

Wednesday, November 18, 2009

AHA - all the fun of the fair


The cavernous exhibit floor, dubbed "The Science and Technology Hall," featured an inflatable, walk-through mega-heart (see a mitral valve prolapse!), a "healthy lifestyles" section anchored by Hershey's ("dark chocolate is good for you") and endless rows of eye-catching drug company displays.

At the Plavix booth, sales reps worked the crowd while an overhead screen showed blobs of plaque winding down a sinuous red artery in need of a blood thinner.

AstraZeneca's Crestor had its name up in lights, along with a reminder that it had the "lowest average co-pay compared to Lipitor and Vytorin."

Pfizer touted both its best-selling cholesterol drug Lipitor and smoking-cessation pill Chantix. Docs waited in line for the Pfizer giveaway: Get your photo taken in a lab coat and we'll put it on a poster for your office.

More from Kris Hundley

Wednesday, July 01, 2009

Pfizer - Chantix: at last!



The Food and Drug Administration will require Pfizer's smoking cessation drug Chantix to carry the agency's strongest safety warning over a series of mental health side effects, including depression and suicidal thoughts.

The new requirement is based on reports of people experiencing unusual changes in behavior, becoming depressed, or having suicidal thoughts while taking the drug.

Pfizer had already updated the drug's labeling, following the beginning of an FDA investigation into the potential side effects in 2007.

The FDA is also requiring an additional study on the drugs to determine the extent of the side effects.

Tuesday, April 28, 2009

Pfizer - Chantix: don't mention the side effects!


A Pfizer promotional campaign for the controversial drug Chantix - which includes financing a course for doctors through the University of Wisconsin-Madison - has helped the drug dominate the prescription smoking-treatment market while burying mention of its serious side effects.

Chantix now accounts for 90% of smoking cessation prescriptions, even though the Food and Drug Administration has been investigating the drug for a rash of serious side effects, such as suicidal behavior and blackouts.

None of the side effects are mentioned in the UW continuing education online course, which is paid for by Pfizer. The course directly mentions only Chantix as a first-line treatment, even though the drug is one of seven first-line treatments, according to national guidelines.

Further, organizations such as the Department of Veterans Affairs, say Chantix should not be considered as a first-line treatment.

More

Tuesday, February 24, 2009

Pharmafocus - 20 20 hindsight!

In retrospect, Pfizer's move to buy another major pharmaceutical company was inevitable. Like its peers, Pfizer has been energetically restructuring itself in recent times, from its salesforces to its R&D, but the fruits of these reforms cannot come quickly enough.

When Lipitor's US patent expires in 2011, it is set to lose most of its current $12 billion annual revenue in the space of just a few years. Meanwhile, other patent expiries and the relative failure of products like smoking cessation drug Champix/Chantix means there is nothing in the company's portfolio to replace it.

Pfizer's acquisitive approach to growth has set the pace for the industry over the last decade, and it is obvious that at least some of its peers could now follow its latest example.

Who? Go here.

Monday, November 10, 2008

Pfizer - Chantix / Champix: 10 UK suicides

UK Health chiefs have revealed that ten people have committed suicide after taking a controversial anti-smoking drug linked to depression.

The disclosure by the Government’s drugs watchdog is the first time officials have revealed the link between Champix and suicide in this country. Earlier this year, US authorities announced they were investigating 37 similar cases there.

The Medicines and Healthcare products Regulatory Agency (MHRA) website says a total of 24 people taking the nicotine-replacement have died, of whom ten took their own lives.

A further 213 claimed they had experienced suicidal thoughts and 407 said they were suffering depression.

More